EnsiliTech

# EnsiliTech: High-Level Overview

EnsiliTech is a biotechnology company that develops patented technology to eliminate cold-chain requirements for storing and transporting life-saving biopharmaceuticals.[1][2] Founded in 2022 as a spinout from the University of Bath, the Bristol-based startup has developed Ensilication®, a proprietary formulation technology that encases vaccines, antibodies, enzymes, and other biologics within a protective silica network, allowing them to remain stable at temperatures ranging from –80°C to +50°C without refrigeration.[2][3]

The company addresses a critical global problem: the cold chain—the network of refrigerators and freezers required to transport and store biological medicines—is expensive, environmentally damaging, and prone to failure. Cold chain failures result in approximately 1.5 million infant deaths annually and cost the pharmaceutical industry roughly $35 billion per year, while accounting for up to 90% of vaccination program emissions.[3] EnsiliTech's technology eliminates this dependency, making life-saving medicines accessible in underserved regions where reliable refrigeration infrastructure is unavailable, while simultaneously reducing supply-chain costs, drug waste, and environmental impact.

# Origin Story

EnsiliTech emerged from academic research at the University of Bath, where co-founder and CEO Dr. Asel Sartbaeva worked as a researcher in the Department of Chemistry.[2] The company officially spun out from the university in July 2022.[1] In December 2022, EnsiliTech completed an oversubscribed pre-seed investment round of £1.2 million ($1.5 million), comprising an Innovate UK grant and private investment from Science Angels Syndicate, Fink Family Office, QantX, and angel investors.[1] The company has since raised additional capital, including €5.2 million in a subsequent funding round as of August 2025.[6]

The progression from academic publication to commercial licensing negotiations occurred within three years, demonstrating rapid de-risking of technical, regulatory, and commercial challenges.[2]

# Core Differentiators

• Proprietary silica-based encapsulation: Unlike other stabilization technologies, Ensilication does not rely on lyophilisation or harsh conditions. Instead, it applies tiny layers of silica—the material from which sand is made—around biological molecules, creating protective "cages" that keep active ingredients intact regardless of temperature or humidity variations.[2][3]

• Broad applicability: The technology is designed for both existing and new biopharmaceutical formulations and can be applied to vaccines, antibodies, enzymes, mRNA therapies, and diagnostic biologicals for human, animal, and laboratory use.[2][3]

• Biocompatibility and cost-effectiveness: Silica is biocompatible, inert, and inexpensive. When the medicine is administered, the silica cage cracks open and falls away, leaving the active ingredient in its pure, fully functional form.[2]

• Market recognition: EnsiliTech achieved a landmark sweep at the 2025 South West Startup Awards, winning Overall Startup of the Year South West, Innovative Startup of the Year, and MedTech & HealthTech Startup of the Year.[1]

# Role in the Broader Tech Landscape

EnsiliTech operates at the intersection of three powerful trends: global health equity, supply-chain resilience, and climate sustainability. The company is positioned to unlock new markets for vaccines, mRNA therapies, and antibodies in low-resource regions where cold-chain infrastructure remains a fundamental barrier to healthcare access. This timing is particularly significant given increased global investment in pandemic preparedness, mRNA technology adoption, and climate-conscious pharmaceutical logistics.

The startup exemplifies a broader shift in biotech toward solving infrastructure-dependent problems rather than purely molecular innovation. By removing the cold-chain requirement, EnsiliTech enables pharmaceutical companies to expand addressable markets while simultaneously reducing operational costs and environmental footprint—a rare alignment of commercial and social incentives that appeals to both traditional investors and impact-focused capital.

# Quick Take & Future Outlook

EnsiliTech is well-positioned to become the category leader in biologics thermostabilization.[2] The company's trajectory suggests expansion from early-stage validation toward licensing partnerships with major pharmaceutical manufacturers. Key milestones ahead likely include regulatory approvals for specific therapeutic applications, commercial partnerships with vaccine manufacturers and biopharmaceutical companies, and potential scaling into adjacent markets such as veterinary biologics and laboratory diagnostics.

The broader significance of EnsiliTech extends beyond its commercial potential: success would fundamentally reshape global pharmaceutical logistics, making life-saving medicines accessible in regions where geography and infrastructure have historically determined healthcare outcomes. In this sense, the company represents a rare opportunity where technological innovation directly translates to measurable improvements in global health equity.